Neurology News

The effects of climate change break down epithelial barriers, enabling pollutants and other materials to penetrate the body and trigger or exacerbate autoimmune diseases, according to a review published in Frontiers in Science.

DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Children from underrepresented groups with migraine received fewer diagnoses, imaging, tests and medication compared with their white counterparts, according to a poster at the American Academy of Neurology annual meeting.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.

DENVER — Cognitive impairment in Parkinson’s is a mitigating factor for presence of blood-based biomarkers during sleep as indicator of disease progression, according to a poster at the American Academy of Neurology annual meeting.

In a 3-2 vote, the Federal Trade Commission passed a final rule that bans new noncompete agreements with all workers in for-profit organizations.

The FDA granted accelerated approval to Ojemda for the treatment of certain children with relapsed or refractory low-grade glioma.

DENVER — For those experiencing chronic migraine, the presence of self-reported psychiatric conditions did not affect the effectiveness of eptinezumab, according to a poster at the American Academy of Neurology annual meeting.

The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.

Therapist burnout was associated with lower odds of clinically meaningful improvement among patients being treated for PTSD, according to a study published in JAMA Network Open.